Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children.

BACKGROUND: The World Health Organization has recently targeted the elimination of trachoma as a public health problem by the year 2020. Community-based treatment with antibiotics, including oral azithromycin, is recommended for severely affected communities. The incidence of adverse effects after azithromycin treatment is not known in trachoma endemic communities. METHODS: We compared the effects of azithromycin with those of topical tetracycline given as mass treatment for trachoma on childhood morbidity in eight rural Gambian villages. The entire population of four villages received oral azithromycin suspension (Zithromax, Pfizer) in doses of 20 mg/kg on Days 1, 8 and 15; the other four villages received topical tetracycline eye ointment for 42 days. Morbidity surveys of subjects 3 months to 14 years old were conducted on Days 0, 7, 14, 21 and 28. RESULTS: Of the 804 subjects recruited complete follow-up data were available on 791 (412 azithromycin, 379 tetracycline). Fever and headache were the most common complaints. Apart from cough other symptoms were equally prevalent in both groups at baseline. The azithromycin group had 20% fewer illness, fever and headache episodes and 40% fewer diarrhea and vomiting episodes at follow-up than did the tetracycline group. CONCLUSIONS: Azithromycin treatment for trachoma had favorable short term effects on childhood morbidity in rural Gambian villages, particularly in the high malaria transmission season, and adverse effects were not a problem.

A population-based hepatitis B seroprevalence and risk factor study in a northern Ontario town.

OBJECTIVE: To determine a) population-based hepatitis B seroprevalence rates; and b) associated behavioural risk factors. SETTING: A remote northern Ontario town with a cluster of hepatitis B cases. INTERVENTIONS: Anonymous blood testing linked with risk-factor questionnaires. RESULTS: 635 persons aged 14 to 30 years (51% of the eligible age cohort) donated blood in return for free vaccination; four were anti-HBs positive, and none was HBsAg positive. In all, 19% of participants reported two or more sexual partners in the previous year, 6% reported at least one tattooing in the previous year, and 1% reported illicit injection drug use. Of persons with multiple sexual partners 84% did not consistently use condoms. CONCLUSIONS: When the serological results of the original cluster (and contacts) were considered, the age cohort's HBsAg seroprevalence rate was estimated to be between 0.24% and 0.47%. While the serosurvey did not discover additional HBsAg positive cases, there was great potential for heterosexual transmission.

Effects of azithromycin on malariometric indices in The Gambia.

Azithromycin (a macrolide-like antibiotic) has antimalarial effects in vitro and in animal models. In the course of a randomised trial of trachoma control we examined the effects of azithromycin on parasite and spleen rates in the population aged 5-14 years from eight villages in the Farafenni study area in The Gambia, West Africa. The entire population of four treatment villages received three doses of azithromycin 20 mg/kg weekly (days 1, 8, and 15) and four control villages received daily tetracycline eye ointment topically (days 1-42). Among 226 children studied before treatment and at day 28, azithromycin reduced the proportions with Plasmodium falciparum parasites (rate ratio 0.56, 95% confidence interval 0.44-0.71; p < 0.0001), with palpable spleens (RR 0.50, 95% CI 0.36-0.70; p < 0.0001), with febrile parasitaemia (RR 0.45, 95% CI 0.27-0.75; p < 0.01), and with P malariae infection (p < 0.001). This effect was related more to resolution of parasitaemia than to prevention of new infections.